Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akio Imanishi

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Pharmacological Sciences|September 28, 2011
Bidirectional regulation of human colonic smooth muscle contractility by tachykinin NK(2) receptorsAkihiro Nakamura, Takahiro Tanaka, Akio Imanishi, et al.
Experimental and Clinical Cardiology|July 31, 2009
Risk factors for coronary artery sclerosis in patients with diabetesAkihiro Nishiyama, Chihiro Shikata, Nobuaki Kimura, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2019
Discovery of novel 4-phenyl-2-(pyrrolidinyl)nicotinamide derivatives as potent Na<sub>v</sub>1.1 activatorsTohru Miyazaki, Masanori Kawasaki, Atsushi Suzuki, et al.
Toxicology|July 6, 2020
Freshly isolated primary human proximal tubule cells as an in vitro model for the detection of renal tubular toxicityPiyush Bajaj, Git Chung, Keith Pye, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 10, 2021
Increasing Effects of Selective 5-Hydroxytryptamine Type 2C Receptor Stimulation on Evoked Momentary Urethral Closure in Female Rats and HumansIzumi Kamo, Hiroshi Nagata, Gale O'Connell, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 14, 2010
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseasesYasunobu Hori, Akio Imanishi, Jun Matsukawa, et al.
Experimental and Therapeutic Medicine|December 2, 2015
Different training status may alter the continuous blood glucose kinetics in self-paced endurance runningYoshio Suzuki, Tomomi Shimizu, Makoto Ota, et al.
Bioorganic & Medicinal Chemistry Letters|April 21, 2015
Synthetic studies of five-membered heteroaromatic derivatives as potassium-competitive acid blockers (P-CABs)Yasuyoshi Arikawa, Atsushi Hasuoka, Haruyuki Nishida, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|February 21, 2023
The mechanism of thrombocytopenia caused by cholesterol-conjugated antisense oligonucleotidesKosuke Harada, Hideki Furukawa, Hiroshi Kohara, et al.
Journal of Pharmacological Sciences|March 27, 2012
Establishment and validation of a rabbit model for in vivo pharmacodynamic screening of tachykinin NK2 antagonistsTakahiro Tanaka, Shiho Matsumoto-Okano, Nobuhiro Inatomi, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Pharmacological Sciences|September 28, 2011
Bidirectional regulation of human colonic smooth muscle contractility by tachykinin NK(2) receptorsAkihiro Nakamura, Takahiro Tanaka, Akio Imanishi, et al.
Experimental and Clinical Cardiology|July 31, 2009
Risk factors for coronary artery sclerosis in patients with diabetesAkihiro Nishiyama, Chihiro Shikata, Nobuaki Kimura, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2019
Discovery of novel 4-phenyl-2-(pyrrolidinyl)nicotinamide derivatives as potent Na<sub>v</sub>1.1 activatorsTohru Miyazaki, Masanori Kawasaki, Atsushi Suzuki, et al.
Toxicology|July 6, 2020
Freshly isolated primary human proximal tubule cells as an in vitro model for the detection of renal tubular toxicityPiyush Bajaj, Git Chung, Keith Pye, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 10, 2021
Increasing Effects of Selective 5-Hydroxytryptamine Type 2C Receptor Stimulation on Evoked Momentary Urethral Closure in Female Rats and HumansIzumi Kamo, Hiroshi Nagata, Gale O'Connell, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 14, 2010
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseasesYasunobu Hori, Akio Imanishi, Jun Matsukawa, et al.
Experimental and Therapeutic Medicine|December 2, 2015
Different training status may alter the continuous blood glucose kinetics in self-paced endurance runningYoshio Suzuki, Tomomi Shimizu, Makoto Ota, et al.
Bioorganic & Medicinal Chemistry Letters|April 21, 2015
Synthetic studies of five-membered heteroaromatic derivatives as potassium-competitive acid blockers (P-CABs)Yasuyoshi Arikawa, Atsushi Hasuoka, Haruyuki Nishida, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|February 21, 2023
The mechanism of thrombocytopenia caused by cholesterol-conjugated antisense oligonucleotidesKosuke Harada, Hideki Furukawa, Hiroshi Kohara, et al.
Journal of Pharmacological Sciences|March 27, 2012
Establishment and validation of a rabbit model for in vivo pharmacodynamic screening of tachykinin NK2 antagonistsTakahiro Tanaka, Shiho Matsumoto-Okano, Nobuhiro Inatomi, et al.
Pageof 2